pan-RAS(ON) inhibitor

Adlai Nortye Ltd. (NASDAQ: ANL) will present on AN4035, a novel CEACAM5-targeting antibody-drug conjugate (ADC) armed with a pan-RAS(ON) inhibitor, at the AACR-NCI-EORTC conference on October 25, 2025. The presentation will highlight the company’s efforts to develop innovative cancer therapies and address challenging targets like RAS. Further details on AN4035’s scientific rationale and data will be released after the abstract is published on October 22, 2025. AN4035 is designed to potentially broaden the therapeutic window in treating RAS-driven cancers.